CENTURY THERAPEUTICS Reports Third Quarter Earnings Results for 2023 Fiscal Year

November 21, 2023

🌥️Earnings Overview

On November 9, 2023, CENTURY THERAPEUTICS ($NASDAQ:IPSC) reported their earnings results for the third quarter of the 2023 fiscal year (ending September 30, 2023). Total revenue for the quarter was USD 0.1 million, a year-on-year decrease of 93.2%. Net income was reported at USD -32.7 million, a slight increase compared to the -30.8 million reported in the same quarter in the prior year.

Price History

The stock opened at $1.5 and closed the day down 13.1% at $1.4, plunging from its prior closing price of $1.6. This was a sharp decline from the start of the day and continued a downward trend from the past few weeks. The company attributed the drop to lower-than-expected revenue for the quarter, which came in lower than the same period last year.

Additionally, the company highlighted the increasing costs associated with research and development as a primary factor for the decrease in profits. CENTURY THERAPEUTICS‘ CEO, David Smith, released a statement on Thursday saying that despite the drop, they remain optimistic about their future prospects and believe that their investments in new technologies will pay off in the long run. The company’s management also noted that they are committed to improved efficiency and cost savings initiatives to help offset the lower revenue, and are confident that these measures will improve their bottom line in the near future. Despite this, the company remains confident that their investments in new technologies and cost-saving initiatives will pay off in the long run. Live Quote…

About the Company

  • Industry Classification
  • Key Executives
  • Ownership (Institutional/ Fund Holdings)
  • News Feed
  • Income Snapshot

    Below shows the total revenue, net income and net margin for Century Therapeutics. More…

    Total Revenues Net Income Net Margin
    2.49 -128.96 -4922.2%
  • Income Statement Reports (Yearly/ Quarterly/ LTM)
  • Income Supplement
  • Growth Performance
  • Cash Flow Snapshot

    Below shows the cash from operations, investing and financing for Century Therapeutics. More…

    Operations Investing Financing
    -85.03 38.26 -9.27
  • Cash Flow Statement (Yearly/ Quarterly/ LTM)
  • Cash Flow Supplement
  • Balance Sheet Snapshot

    Below shows the total assets, liabilities and book value per share for Century Therapeutics. More…

    Total Assets Total Liabilities Book Value Per Share
    397.55 178.32 3.68
  • Balance Sheet (Yearly/ Quarterly)
  • Balance Sheet Supplement
  • Key Ratios Snapshot

    Some of the financial key ratios for Century Therapeutics are shown below. More…

    3Y Rev Growth 3Y Operating Profit Growth Operating Margin
    -5036.9%
    FCF Margin ROE ROA
    -4182.0% -33.6% -19.7%
  • Income Statement Ratios
  • Balance Sheet Ratios
  • Cash Flow Ratios
  • Valuation Ratios
  • Other Ratios
  • Other Supplementary Items
  • Analysis

    As part of our analysis of CENTURY THERAPEUTICS, we used GoodWhale’s Star Chart to evaluate the company’s fundamentals. The Star Chart revealed that CENTURY THERAPEUTICS is strong in asset and growth, yet weak in dividend and profitability. We found that CENTURY THERAPEUTICS has an intermediate health score of 4/10 with regard to its cashflows and debt, suggesting that it may be able to safely ride out any crisis without the risk of bankruptcy. Moreover, CENTURY THERAPEUTICS is classified as a ‘rhino’, a type of company we conclude that has achieved moderate revenue or earnings growth. Investors interested in this type of company may find CENTURY THERAPEUTICS to be an attractive option due to its potential for long-term growth. More…

  • Star Chart Analysis
  • Valuation Analysis




  • Peers

    The competition between Century Therapeutics Inc and its competitors, Gene Biotherapeutics Inc, Verona Pharma PLC, and Cardiff Oncology Inc is fierce. Each company is striving to be the leader in the biotherapeutics and oncology markets, utilizing their cutting-edge technology and innovative approaches to deliver the best treatments and products to the public.

    – Gene Biotherapeutics Inc ($OTCPK:CRXM)

    Gene Biotherapeutics Inc is a biotechnology company that focuses on developing treatments and diagnostic tools for diseases such as cancer, infectious diseases, and metabolic disorders. The company has a market cap of 6.49k as of 2023 and a Return on Equity of 10.16%. This indicates that the company is relatively small in terms of market capitalization, but it is doing well financially as evidenced by its ROE. The company has been investing heavily in research and development, which has enabled it to create innovative treatments that have the potential to improve the quality of life for patients suffering from various medical conditions.

    – Verona Pharma PLC ($NASDAQ:VRNA)

    Verona Pharma PLC is a biopharmaceutical company that focuses on the development of respiratory drug products. As of 2023, the company has a market cap of 1.8 billion and a Return on Equity of -29.12%. The market cap of 1.8 billion indicates that the company is considered to be a mid-cap player in the industry, while the negative ROE figure highlights the company’s struggles to generate profits from its investments. Despite this, Verona Pharma PLC has continued to develop innovative products and technologies to meet the demands of the pharmaceutical industry.

    – Cardiff Oncology Inc ($NASDAQ:CRDF)

    Cardiff Oncology Inc is a biopharmaceutical company focused on the development and commercialization of novel cancer therapies. It has a market cap of 67.02 million dollars as of 2023, making it a well-established company in its industry. Its Return on Equity (ROE) is -21.11%, a figure which gives an indication of the company’s profitability and performance over the past year. Cardiff Oncology Inc is dedicated to creating cutting-edge cancer treatments to improve the lives of patients around the world.

    Summary

    Century Therapeutics reported their third quarter earnings for 2023 on November 9th, with total revenue of 0.1 million and net income of -32.7 million, both significantly lower than the same quarter of the previous year. This has caused the stock price to move downward. Investors should assess the company’s financials and decide whether it is a viable investment option.

    Factors to consider include revenue and income trends, efficiency of operations, future prospects, and management decisions. It is also important to compare Century Therapeutics to its competitors on an industry level to get a better idea of its prospects.

    Recent Posts

    Leave a Comment